Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own. -
IV fluids used in hospitals remain in short supply, after Hurricane Helene shut down a key North Carolina factory. The closure has hospitals scrambling to stretch supplies and prioritize care. -
After Hurricane Helene flooded an IV fluid factory in North Carolina, the government and industry are trying to mitigate shortages. -
Remnants of Hurricane Helene shut down a North Carolina factory that supplies critical IV fluids to hospitals across the country. There's no timeline for when production will resume at the facility. -
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday. -
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially inflated the cost of insulin. -
The drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be over, but many patients still have trouble getting the medicines. -
The White House announced new Medicare drug prices for 10 medicines popular with beneficiaries. It's the first time the federal program has negotiated lower prices with the pharmaceutical industry. -
Medicare's new authority to negotiate lower prescription drug prices represents a signature accomplishment of the Biden-Harris administration. Here's what to know as the first set of talks wraps up. -
Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.
